
As approximately 70% of our newly diagnosed people with MS go onto ocrelizumab (a CD20 and thus B cell-depleting monoclonal antibody), a study that helps us understand how ocrelizumab affects the potential to mount (protective) antibody responses to vaccines and new antigens is more than welcome. Especially, as we are all hoping for the COVID-19 vaccine to be under the Christmas tree. B...